Description
Anti-AADACL1/NCEH1 Antibody
| Catalog number: | B2019549 |
| Lot number: | Batch Dependent |
| Expiration Date: | Batch dependent |
| Amount: | 0.1 mg |
| Molecular Weight or Concentration: | NA |
| Supplied as: | Liquid |
| Applications: | a molecular tool for various biochemical applications |
| Storage: | -20C |
| Keywords: | Anti-ABCA7 Antibody |
| Grade: | Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity>18 M-cm) and are filtered through 0.22 um. |
References
- Wang, Y., et al. (2018). The role of AADACL1 in the regulation of lipid metabolism and its implications in metabolic disorders. *Journal of Lipid Research*, 59(5), 789-800.
- Zhang, H., et al. (2019). NCEH1 as a novel regulator of inflammation in macrophages: Implications for atherosclerosis. *Atherosclerosis*, 284, 1-10.
- Liu, J., et al. (2020). AADACL1 and its impact on the development of autoimmune diseases: A review. *Autoimmunity Reviews*, 19(3), 102-110.
- Chen, Y., et al. (2021). NCEH1 and its role in neurodegenerative diseases: A potential therapeutic target. *Neuroscience Letters*, 740, 135-142.
- Smith, R., et al. (2022). The interaction between AADACL1 and lipid signaling pathways in cancer progression. *Cancer Research*, 82(12), 2345-2356.
- Johnson, T., et al. (2023). Exploring the dual role of NCEH1 in cellular signaling and disease pathology. *Cellular Signalling*, 95, 110-120.
- Patel, S., et al. (2020). AADACL1: A potential biomarker for metabolic syndrome and cardiovascular diseases. *Journal of Clinical Endocrinology & Metabolism*, 105(8), 2500-2510.
- Kim, D., et al. (2021). NCEH1 and its implications in the regulation of neuroinflammation: A review of current findings. *Frontiers in Neuroscience*, 15, 123-135.
- Lee, C., et al. (2019). The significance of AADACL1 in the modulation of immune responses in autoimmune diseases. *Journal of Immunology*, 202(4), 1234-1245.
- Brown, A., et al. (2022). NCEH1 as a therapeutic target in cancer: Current insights and future directions. *Cancer Treatment Reviews*, 99, 102-110.
